Pipelines are shrinking, blockbuster drugs are
going off-patent and the global pharmaceutical industry is seeing much more
competition from emerging market companies.
So how are you going to add value to your company’s pipeline?
At the 17th Annual Drug Delivery Partnerships
we can help you …
• Develop strategies and priorities for
investing in drug delivery technologies
• Understand the most important technologies
and companies involved in developing new drug delivery technologies in key
therapeutic areas.
What are some highlighted sessions for you to
consider attending to accelerate your drugs to market and lengthen lifecycles
for long term profitability?
KEYNOTE PRESENTATION: When Drug Delivery
Creates a Blockbuster presented by Mr. David Pyott Chairman, President and CEO
of Allergan
About the session: Allergan has a long history
of success in the biopharmaceutical industry and drug delivery has played a key
role in several areas of the company’s pipeline. The company has achieved
extraordinary market success with Botox and in eye care specifically and the
delivery of those products has allowed them to become billion dollar
investments.
In this keynote presentation, the, discusses
how Allergan achieved these successes and others and how drug delivery has
played an essential role.
FEATURED KEYNOTE PANEL: Where Does Drug
Delivery Fit into the Pharmaceutical Pipeline?
Panelists: Christopher Seaton, SVP, Global
Licensing, BAYER PHARMACEUTICALS, James Hattersley, Vice President, Corporate
Business Development, SUN PHARMACEUTICALS, Chris Jones, Vice President and
Global Head, Pharmaceutical Development, ASTRAZENECA
About the session: Those working in pharma
know how important drug delivery is for pipeline development, but have to get
buy-in from senior management to get those important resources for development.
This executive keynote panel discusses and debates:
• Differentiation as the key goal in
developing and seeking out new technologies
• What is the FDA going to allow and how tough
will it be to get things through?
• How is the rise of generics affecting the
delivery strategy?
• How is the idea of “innovation” continuing
to drive company strategy?
Moderator: Roy Waldron, Senior Vice President
and Associate General Counsel, PFIZER
To find out more about these sessions and the
rest of the program, download the agenda: http://bit.ly/RBQlJL
As a reader of this blog, you get a 15% discount off the
standard rate when you register
to join us when
using code XP1878BLOG. If
you have any questions about the agenda or event, please contact Jennifer
Pereira at jpereira@iirusa.com or
visit our webpage here: http://bit.ly/RU9k2G
Cheers,
The Drug Delivery Partnerships International
Team
No comments:
Post a Comment